(IBIO) iBio Common Stock - Ratings and Ratios
Exchange: NYSE MKT • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4510332038
IBIO: Antibodies, Cancer, Cardiometabolic, AI, Biotech, Collaboration
iBio, Inc. (NYSE MKT:IBIO), a preclinical-stage biotechnology company, specializes in developing AI-driven antibody solutions for cancer and other diseases. The companys technology platforms include EngageTx, which enhances CD3 T-cell engager antibody panels for improved immune targeting; ShieldTx, an antibody masking technology that enables conditionally activated antibodies to reduce off-tumor effects; StableHu, an AI-optimized antibody platform for stability and efficacy; and AI epitope steering technology, which directs antibodies to specific regions of target proteins for precise engagement.
The companys product pipeline focuses on cardiometabolic diseases and oncology. Key candidates include IBIO-101, an anti-CD25 monoclonal antibody designed to deplete immunosuppressive regulatory T cells (Tregs) and inhibit tumor growth; CCR8, an antibody that enhances immune response against cancer cells; and Trophoblast Cell Surface Antigen 2 (TROP2), a monoclonal antibody targeting solid tumors. Additionally, the company is advancing EGFRvIII, an antibody therapeutic targeting the EGFRvIII protein in glioblastoma and other cancers, with a focus on minimizing impact on healthy cells. iBio also collaborates with AstralBio to discover and develop novel antibodies for obesity and cardiometabolic diseases.
Founded in 2008 and headquartered in San Diego, California, iBio, Inc. leverages its proprietary AI and antibody engineering technologies to address unmet medical needs in oncology and metabolic disorders. The companys strategic focus is on precision medicine and innovative antibody solutions.
Additional Sources for IBIO Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
IBIO Stock Overview
| Market Cap in USD | 9m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2008-08-19 |
IBIO Stock Ratings
| Growth Rating | -67.4 |
| Fundamental | - |
| Dividend Rating | 0.0 |
| Rel. Strength | -52.2 |
| Analysts | 5/5 |
| Fair Price Momentum | 0.28 USD |
| Fair Price DCF | - |
IBIO Dividends
No Dividends PaidIBIO Growth Ratios
| Growth Correlation 3m | -68% |
| Growth Correlation 12m | 31.8% |
| Growth Correlation 5y | -95.2% |
| CAGR 5y | -73.15% |
| CAGR/Max DD 5y | -0.73 |
| Sharpe Ratio 12m | -0.91 |
| Alpha | -65.62 |
| Beta | 0.450 |
| Volatility | 132.87% |
| Current Volume | 420.9k |
| Average Volume 20d | 671.2k |
As of May 10, 2025, the stock is trading at USD 0.77 with a total of 420,945 shares traded.
Over the past week, the price has changed by -23.44%, over one month by -39.59%, over three months by -77.39% and over the past year by -58.87%.
No, based on ValueRay Analyses, iBio Common Stock (NYSE MKT:IBIO) is currently (May 2025) a stock to sell. It has a ValueRay Growth Rating of -67.40 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IBIO as of May 2025 is 0.28. This means that IBIO is currently overvalued and has a potential downside of -63.64%.
iBio Common Stock has received a consensus analysts rating of 5.00. Therefor, it is recommend to buy IBIO.
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, IBIO iBio Common Stock will be worth about 0.3 in May 2026. The stock is currently trading at 0.77. This means that the stock has a potential downside of -59.74%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 4.8 | 523.4% |
| Analysts Target Price | 4.3 | 458.4% |
| ValueRay Target Price | 0.3 | -59.7% |